



9 September 2025

Our Ref: FOI 1288

Dear

**Freedom of Information Act 2000
Information in relation to Oncology**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for information relating to above which you requested on 17 July 2025. Please accept my apologies for the delay in responding to your request. Thank you for your understanding and forbearance.

A response to each of the questions raised has been provided by the Medicine, Unscheduled Care and Cancer Services Directorate and is attached in Appendix A.

If you are unhappy as to how this request has been handled, you have the right to seek a review within the Trust in the first instance. You should write to the Information Governance Department, Lough House, Ards Community Hospital (informationgovernance@setrust.hscni.net) within two months of the date of this response and your complaint will be considered and a response provided, within 20 working days of receipt.

If, after receiving a response, you remain unhappy, you can refer your complaint to the Information Commissioner at The Information Commissioner's Office –Northern Ireland, 3rd Floor, 14 Cromac Place, Belfast, BT7 2JB. It is important to note that if you refer any matter to the Information Commissioner, you will need to show evidence of having gone through the Trust's internal review procedure to try to resolve the matter with the Trust in the first instance.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

Rebecca Manning
Information Governance Officer

Q1. How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with following listed in table 1?

A1. Please see Table 1.

Table 1

Treatment	No. of Patients Treated
Atezolizumab (Tecentriq)	1
Durvalumab (Imfinzi)	2
Nivolumab (Opdivo)	2
Pembrolizumab (Keytruda)	19
Osimertinib	6

Please note, in relation to the following treatments, the information requested is not held on a central information system. To obtain this information would require a manual review of records.

This would exceed the 'Appropriate Limit' as defined by the Freedom of Information Act 2000. The Trust therefore exempts the release of this information under Section 12(1).

*12.-(1) Section 1(1) does not oblige a public authority to comply with a request for information if the authority estimates that the cost of complying with the request would exceed the appropriate limit.

- Chemotherapy
- Radiotherapy
- Chemotherapy AND Radiotherapy

Q2. How many patients has your trust treated in the last 3 months with Pembrolizumab for stage II Melanoma?

A2. There have been no patients treated in the last three months with Pembrolizimab for stage II Melanoma, within the Trust.

Q3. How many patients has your Trust treated in total in the past 3 months for:

- **Stage 2 Non-Small Cell Lung Cancer**
- **Stage 3 Non-Small Cell Lung Cancer**

A3. The information requested is not held on a central information system. To obtain this information would require a manual review of records.

This would exceed the 'Appropriate Limit' as defined by the Freedom of Information Act 2000. The Trust therefore exempts the release of this information under Section 12(1).*

Q4. How many Stage 2-3 non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with the following listed in table 3?

A4. Please see Table 3.

Table 3

Treatment	No. of Patients Treated
Atezolizumab	1
Pembrolizumab monotherapy	6
Pembrolizumab with chemotherapy	2
Nivolumab	1
Osimertinib	6
Durvalumab	2

Please note, as per A1 the information requested for the following treatment is not held on a central information system. To obtain this information would require a manual review of records.

- Chemotherapy
- Radiotherapy
- Chemotherapy and Radiotherapy

Q5. How many Stage 2-3 non-small cell lung cancer (NSCLC) patients were treated in the past 3 months following surgery with:

- **Chemotherapy**
- **Radiotherapy**
- **Chemotherapy + Radiotherapy**

Q6. How many Stage 2-3 resectable non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

- **Durvalumab**

A5,6. In response to questions 5 and 6, the information requested is not held on a central information system. To obtain this information would require a manual review of records.

This would exceed the 'Appropriate Limit' as defined by the Freedom of Information Act 2000. The Trust therefore exempts the release of this information under Section 12(1).

In accordance with the Freedom of Information Act 2000 this statement acts as a Refusal Notice in respect of part of the information requested within questions 1 & 4 and the full content for questions 3, 5 & 6.